Firm at a glance
Alantra is a platform private equity firm with offices across Europe, the U.S., Latin America, Asia, and the Middle East, per its own website [S1]. The firm reports approximately €2.7 billion in assets under management in direct investments as of January 2025 [S1].
What they buy
Public transaction records show Alantra acquiring businesses across multiple geographies and sectors. Recent activity includes a September 2024 acquisition of 13 dental laboratories, suggesting interest in healthcare services consolidation [S2]. The firm’s exit of Maple Donuts in June 2025 indicates prior involvement in consumer-facing food businesses [S3].
Portfolio
No current portfolio companies were surfaced in publicly available materials reviewed as of January 2025. The firm’s website and recent press releases did not disclose a comprehensive portfolio list at the time of this review.
Recent activity (last 24 months)
* **September 2024**: Acquired 13 dental laboratories as the second investment from Alantra Private Equity’s fourth fund [S2]
* **June 2025**: Exited Maple Donuts through a sale to Swander Pace Capital [S3]
* **March 2026**: Exited Access Capital Partners [S1]
How this firm fits a seller
Alantra’s multi-continental office network may appeal to sellers seeking a buyer with international reach and cross-border transaction experience. The firm’s recent dental laboratory acquisition demonstrates a willingness to execute multi-unit consolidation strategies, which could suit fragmented service sectors. For business owners in healthcare services or consumer businesses exploring a sale, Alantra’s transaction history suggests familiarity with these verticals, though the firm’s broader investment criteria remain undisclosed in public materials.
Sources
[S1] https://alantra.com (as of 2025-01-15)
[S2] https://www.alantra.com/alantra-private-equitys-fourth-fund-completes-second-investment-with-the-simultaneous-acquisition-of-13-dental-laboratories/ (as of 2025-01-15)
[S3] https://www.alantra.com/ib-transaction/maple-donuts-sell-side-advisory-swander-pace-capital/ (as of 2025-01-15)
Frequently asked questions
Does Alantra buy healthcare businesses?
Yes, per public sources. In September 2024, Alantra Private Equity’s fourth fund acquired 13 dental laboratories simultaneously, indicating active interest in healthcare services consolidation [S2]. This transaction represents the fund’s second investment, suggesting healthcare remains within the firm’s current investment scope.
What companies has Alantra acquired recently?
The most recent publicly disclosed acquisition is a September 2024 purchase of 13 dental laboratories [S2]. Prior portfolio companies that have since exited include Maple Donuts, sold in June 2025 [S3], and Access Capital Partners, exited in March 2026 [S1].
Where is Alantra based and how big is the firm?
Alantra maintains offices in Europe, the U.S., Latin America, Asia, and the Middle East, per its website [S1]. The firm reports approximately €2.7 billion in assets under management in direct investments as of January 2025 [S1]. Specific headquarters location was not disclosed in reviewed public materials.
Is Alantra still actively acquiring?
Yes, based on recent transaction history. The firm completed an acquisition of 13 dental laboratories in September 2024 as part of its fourth fund’s investment activity [S2], indicating ongoing deal execution within the past 24 months.
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.